Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment

Summary

Information from blood samples may help us for choosing the best treatment in future personalized medicine. Natalizumab (NTZ) a current treatment for MS can be used as a second line therapy if a suboptimal response to disease modifying drugs. When to introduce NTZ is not consensual. The investigators hypothesized that biological information could rationalize choice and thus designed a prospective open label trial to test biological markers before treatment.

Timeline

Start

2009-06

Primary completion

2011-02

Completion

2011-03

Drugs

Indications